Newron Pharmaceuticals S.p.A. (FRA:NP5)

Market Cap	164.03M
Revenue (ttm)	51.39M
Net Income (ttm)	15.84M
Shares Out	n/a
EPS (ttm)	0.77
PE Ratio	10.35
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,373
Average Volume	2,443
Open	7.86
Previous Close	7.93
Day's Range	7.82 - 8.21
52-Week Range	6.03 - 11.90
Beta	n/a
RSI	50.17
Earnings Date	Sep 16, 2025

About Newron Pharmaceuticals

Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson’s in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company’s lead compound includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III cl...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1999
• Employees: 22
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: NP5